Pricing Log in Create free account
Saturday 17 October 2026 Export IDXX’s income statement to Excel — free account

IDEXX Laboratories, Inc.

IDXX Healthcare Diagnostics & Research

IDEXX Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 9.66%, EPS grew 17.2%, free cash flow grew 111.4% and total debt fell 14.3%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years, operating cash flow growth for three.

560.36 13.18 +2.41%
Market cap
$43.1B
P/E
39.1×
Fwd P/E
38.3×
Dividend yield
—
F-score
8/9
Altman Z
24.09
Beneish M
−2.50
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

IDEXX Laboratories, Inc. (IDXX) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
10-Q Jun 30, 2026 P1I2: 34 added · 4 removed · 32 modified
P2I1A: no material changes, the filing says
8-K Aug 4, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 12, 2026 5.03 Amendments to the articles or bylaws; change in fiscal year; 5.07 Submission of matters to a vote of security holders; 9.01 Financial statements and exhibits
10-Q Mar 31, 2026
8-K May 5, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Mar 24, 2026 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits Officer departure
10-K Dec 31, 2025 1: 2 added · 6 removed · 68 modified
1A: 2 added · 2 removed · 65 modified
7: 24 added · 34 removed · 67 modified
8-K Feb 13, 2026 5.02 Departure or appointment of directors or officers
8-K Feb 2, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 11, 2026 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Nov 12, 2025 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Nov 3, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Oct 6, 2025 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
10-K Dec 31, 2024

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.